<?xml version="1.0" encoding="UTF-8"?>
<p>Favipiravir is an antiviral drug approved for the treatment of influenza in Japan due to its activity against a wide spectrum of RNA viruses including coronaviruses [
 <xref rid="REF11" ref-type="bibr">11</xref>]. This drug can effectively inhibit RdRp and has been reported to have activity against SARS-CoV-2 [
 <xref rid="REF4" ref-type="bibr">4</xref>]. There are various ongoing trials with favipiravir and it has also been approved for use in multiple countries (
 <ext-link ext-link-type="uri" xlink:href="ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> identifiers: NCT04351295, NCT04346628, NCT04392973, NCT04387760, NCT04425460, NCT04359615, NCT04445467, NCT04358549, NCT04349241, NCT04310228, NCT04373733, NCT04333589) [
 <xref rid="REF47" ref-type="bibr">47</xref>].
</p>
